(Q58449064)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694370%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

title

153Sm: its use in multiple myeloma and report of a clinical experience (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694370%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694370%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Massimo Di Maio

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694370%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

author name string

Francesco Iuliano

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694370%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Malgorzata Monika Trawinska

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694370%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

language of work or name

English

0 references

publication date

1 September 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694370%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

12 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694370%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694370%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694370%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

1379-1387

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694370%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

cites work

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

Myeloma bone disease and treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

The pathogenesis of the bone disease of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

The treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

The emerging role of novel therapies for the treatment of relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

From the bench to the bedside: emerging new treatments in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

An update on drug combinations for treatment of myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

Treatment of plasma cell dyscrasias with thalidomide and its derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

Antimyeloma activity of heat shock protein-90 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

Zoledronic acid - a multiplicity of anti-cancer action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

The antineoplastic role of bisphosphonates: from basic research to clinical evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

Pain syndromes in haematological malignancies: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

Radioisotopes for the palliation of metastatic bone cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

153Sm-EDTMP for bone pain palliation in skeletal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.9.1379

10.1517/13543784.17.9.1379

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694370%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference